Literature DB >> 32001983

Re-revision total hip arthroplasty: Epidemiology and factors associated with outcomes.

S Yu1, H Saleh1, N Bolz1, J Buza1, R Iorio1, P A Rathod1, R Schwarzkopf1, A J Deshmukh1.   

Abstract

INTRODUCTION: The epidemiology of re-revision total hip arthroplasty (THA) is not yet well-understood. We aim to investigate the epidemiology and risk-factors that are associated with re-revision THA.
METHODS: 288 revision THA were analyzed between 1/2012 and 12/2013. Patients who underwent two or greater revision THA were included. Hips with first-revision due to periprosthetic joint infection (PJI) were excluded. Failure was defined as reoperation.
RESULTS: 51 re-revision patients were available. Mean age was 59.6 (±14.2 years), 32 (67%) females, average BMI of 28.8 (±5.4), and median ASA 2 (23; 55%). The most common re-revision indications were acetabular component loosening (15; 29%), PJI (13; 25%) and instability (9; 18%). The most common indications for first revision in the re-revision population were acetabular component loosening (11; 27%), polyethylene wear (8; 19%) and instability (8; 19%). There was an increased risk of re-revision failure if the re-revision involved exchanging only the head and polyethylene liner (RR = 1.792; p = 0.017), instability was the first-revision indication (RR = 3.000; p < 0.001), and instability was the re-revision indication (RR = 1.867; p = 0.038). If isolated femoral component revision was indicated during the re-revision, there was a decreased risk of failure (RR = 0.268, p = 0.046). 1-year re-revision survival was 54% (23/43). DISCUSSION: Acetabular component loosening, instability, and PJI were the most common indications for re-revision. Revision due to instability is a recurrent problem that leads to re-revision failure. There was a higher infection rate in the re-revision population compared to published revision PJI. A better understanding of the indications and patient factors that are associated with re-revision failures can help align surgeon and patient expectations in this challenging population.
© 2018.

Entities:  

Keywords:  Epidemiology; Revision; Risk-factors; Total hip arthroplasty

Year:  2018        PMID: 32001983      PMCID: PMC6985171          DOI: 10.1016/j.jcot.2018.08.021

Source DB:  PubMed          Journal:  J Clin Orthop Trauma        ISSN: 0976-5662


  16 in total

1.  The influence of patient-related factors and the position of the acetabular component on the rate of dislocation after total hip replacement.

Authors:  S A Paterno; P F Lachiewicz; S S Kelley
Journal:  J Bone Joint Surg Am       Date:  1997-08       Impact factor: 5.284

2.  Failure rates for 4762 revision total hip arthroplasties in the Norwegian Arthroplasty Register.

Authors:  S A Lie; L I Havelin; O N Furnes; L B Engesaeter; S E Vollset
Journal:  J Bone Joint Surg Br       Date:  2004-05

3.  The epidemiology of revision total hip arthroplasty in the United States.

Authors:  Kevin J Bozic; Steven M Kurtz; Edmund Lau; Kevin Ong; Thomas P Vail; Daniel J Berry
Journal:  J Bone Joint Surg Am       Date:  2009-01       Impact factor: 5.284

4.  Revision total hip arthoplasty: factors associated with re-revision surgery.

Authors:  Monti Khatod; Guy Cafri; Maria C S Inacio; Alan L Schepps; Elizabeth W Paxton; Stefano A Bini
Journal:  J Bone Joint Surg Am       Date:  2015-03-04       Impact factor: 5.284

5.  Dislocation after revision total hip arthroplasty : an analysis of risk factors and treatment options.

Authors:  Gregory M Alberton; Whitney A High; Bernard F Morrey
Journal:  J Bone Joint Surg Am       Date:  2002-10       Impact factor: 5.284

6.  Early morbidity after aseptic revision hip arthroplasty in Denmark: a two-year nationwide study.

Authors:  M Lindberg-Larsen; C C Jørgensen; T B Hansen; S Solgaard; H Kehlet
Journal:  Bone Joint J       Date:  2014-11       Impact factor: 5.082

7.  Risk of subsequent revision after primary and revision total joint arthroplasty.

Authors:  Kevin L Ong; Edmund Lau; Jeremy Suggs; Steven M Kurtz; Michael T Manley
Journal:  Clin Orthop Relat Res       Date:  2010-05-25       Impact factor: 4.176

8.  The John Charnley Award. Wear is a function of use, not time.

Authors:  T P Schmalzried; E F Shepherd; F J Dorey; W O Jackson; M dela Rosa; F Fa'vae; H A McKellop; C D McClung; J Martell; J R Moreland; H C Amstutz
Journal:  Clin Orthop Relat Res       Date:  2000-12       Impact factor: 4.176

Review 9.  Femoral Component Revision of Total Hip Arthroplasty.

Authors:  Jonathon M Brown; Jaydev B Mistry; Jeffrey J Cherian; Randa K Elmallah; Morad Chughtai; Steven F Harwin; Michael A Mont
Journal:  Orthopedics       Date:  2016-08-30       Impact factor: 1.390

10.  Revision total hip arthroplasty in octogenarians. A case-control study.

Authors:  Javad Parvizi; Aidin Eslam Pour; Nahid R Keshavarzi; Michele D'Apuzzo; Peter F Sharkey; William J Hozack
Journal:  J Bone Joint Surg Am       Date:  2007-12       Impact factor: 5.284

View more
  4 in total

Review 1.  [Pitfalls in revision hip arthroplasty].

Authors:  Carsten Perka; Rudolf Ascherl
Journal:  Orthopadie (Heidelb)       Date:  2022-07-16

2.  Impact of stem profile on the revisability and the need for osteotomy in well-fixed cemented revision total knee arthroplasty implants.

Authors:  Alexander Maslaris; Georgios Spyrou; Carsten Schoeneberg; Mustafa Citak; Georg Matziolis
Journal:  Arch Orthop Trauma Surg       Date:  2022-08-05       Impact factor: 2.928

Review 3.  Femoral prosthesis fracture after hip arthroplasty revision: A Case Report and Review of Literature.

Authors:  Long Yuan; Sen Li; Wanxiang Li; Jichao Bian; Yahui Bao; Xiaopeng Zhou; Yuanmin Zhang; Wang Li; Guodong Wang
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

4.  The distance between new and previous incisions does not affect skin necrosis in total knee arthroplasty: a parallel-randomized controlled clinical trial.

Authors:  Ali Yeganeh; Mehdi Moghtadaei; Alireza Ghaznavi; Nader Tavakoli; Mohammad Soleimani; Sahand Cheraghiloohesara; Nima Taheri
Journal:  BMC Surg       Date:  2022-09-26       Impact factor: 2.030

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.